Table 3.

Clinical trials with other anti-human epidermal growth factor receptor 2 agents

Setting, therapy line	ID	Phase	n	Treatment	Primary EP	Status
Operable disease	NCT00450203	III	370	Lapatinib, epirubicin, cisplatin, capecitabine	OS	Recruiting
Advanced first line	NCT00680901	III	535	Lapatinib, oxaliplatin, capecitabine	OS	Active, not recruiting
	LOGiC
	NCT01395537	II	43	Lapatinib, carboplatin, paclitaxel	Safety, RR	Active, not recruiting
	NCT01123473	II	192	Lapatinib, epirubicin, cisplatin, capecitabine, 5-FU	PFS	Unknown
	NCT00526669	II	67	Lapatinib, capecitabine	RR	Active, not recruiting
Advanced second line	NCT00486954	III	273	Lapatinib, paclitaxel	OS	Completed
	TYTAN
	NCT01522768	II	27	Afatinib	RR	Recruiting
	NCT01152853	II	28	Dacomitinib	PFS	Unknown
	NCT01145404	II	76	Lapatinib, capecitabine	RR	Active, not recruiting

OS: Overall survival; PFS: Progression-free survival; 5-FU: 5-fluorouracil; RR: Response rate; CR: Complete response; PR: Partial response; NA: Not available.